This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmidt, H.
Right arrow Articles by Nau, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmidt, H.
Right arrow Articles by Nau, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 1998, p. 1397-1401, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Moxifloxacin in the Therapy of Experimental Pneumococcal Meningitis

H. Schmidt,1 A. Dalhoff,2 K. Stuertz,1 F. Trostdorf,1 V. Chen,1 O. Schneider,1 C. Kohlsdorfer,2 W. Brück,3 and R. Nau1,*

Departments of Neurology1 and Neuropathology,3 University of Göttingen, Göttingen, and Bayer AG, Wuppertal,2 Germany

Received 15 October 1997/Returned for modification 13 January 1998/Accepted 13 March 1998

The activity of moxifloxacin (BAY 12-8039) against a Streptococcus pneumoniae type 3 strain (MIC and minimum bactericidal concentration [MBC] of moxifloxacin, 0.06 and 0.25 µg/ml, respectively; MIC and MBC of ceftriaxone, 0.03 and 0.06 µg/ml, respectively) was determined in vitro and in a rabbit model of meningitis. Despite comparable bactericidal activity, 10 µg of moxifloxacin per ml released lipoteichoic and teichoic acids less rapidly than 10 µg of ceftriaxone per ml in vitro. Against experimental meningitis, 10 mg of moxifloxacin per kg of body weight per ml reduced the bacterial titers in cerebrospinal fluid (CSF) almost as rapidly as ceftriaxone did (mean ± standard deviation, -0.32 ± 0.14 versus -0.39 ± 0.11 Delta log CFU/ml/h). The activity of moxifloxacin could be described by a sigmoid dose-response curve with a maximum effect of -0.33 Delta logCFU/ml/h and with a dosage of 1.4 mg/kg/h producing a half-maximal effect. Maximum tumor necrosis factor activity in CSF was observed later with moxifloxacin than with ceftriaxone (5 versus 2 h after the initiation of treatment). At 10 mg/kg/h, the concentrations of moxifloxacin in CSF were 3.8 ± 1.2 µg/ml. Adjunctive treatment with dexamethasone at 1 mg/kg prior to the initiation of antibiotic treatment only marginally reduced the concentrations of moxifloxacin in CSF (3.3 ± 0.6 µg/ml). In conclusion, moxifloxacin may qualify for use in the treatment of S. pneumoniae meningitis.

* Corresponding author. Mailing address: Department of Neurology, University of Göttingen, Robert-Koch-Str. 40, D-37075 Göttingen, Germany. Phone: 49-551-398455. Fax: 49-551-398405. E-mail: rnau{at}gwdg.de.

Antimicrobial Agents and Chemotherapy, June 1998, p. 1397-1401, Vol. 42, No. 6
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Kanellakopoulou, K., Pagoulatou, A., Stroumpoulis, K., Vafiadou, M., Kranidioti, H., Giamarellou, H., Giamarellos-Bourboulis, E. J. (2008). Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. J Antimicrob Chemother 61: 1328-1331 [Abstract] [Full Text]  
  • Sipahi, O. R., Turhan, T., Pullukcu, H., Calik, S., Tasbakan, M., Sipahi, H., Arda, B., Yamazhan, T., Ulusoy, S. (2008). Moxifloxacin versus ampicillin + gentamicin in the therapy of experimental Listeria monocytogenes meningitis. J Antimicrob Chemother 61: 670-673 [Abstract] [Full Text]  
  • El Bashir, H, Laundy, M, Booy, R (2003). Diagnosis and treatment of bacterial meningitis. Arch. Dis. Child. 88: 615-620 [Abstract] [Full Text]  
  • Bronner, S., Jehl, F., Peter, J.-D., Ploy, M.-C., Renault, C., Arvis, P., Monteil, H., Prevost, G. (2003). Moxifloxacin Efficacy and Vitreous Penetration in a Rabbit Model of Staphylococcus aureus Endophthalmitis and Effect on Gene Expression of Leucotoxins and Virulence Regulator Factors. Antimicrob. Agents Chemother. 47: 1621-1629 [Abstract] [Full Text]  
  • Rodriguez-Cerrato, V., McCoig, C. C., Saavedra, J., Barton, T., Michelow, I. C., Hardy, R. D., Bowlware, K., Iglehart, J., Katz, K., McCracken, G. H. Jr (2003). Garenoxacin (BMS-284756) and Moxifloxacin in Experimental Meningitis Caused by Vancomycin-Tolerant Pneumococci. Antimicrob. Agents Chemother. 47: 211-215 [Abstract] [Full Text]  
  • Takahata, M., Yamada, H., Morita, T., Furubou, S., Minami, S., Todo, Y., Watanabe, Y., Narita, H. (2002). Evaluation of T-3811ME (BMS-284756), a New Des-F(6)-Quinolone, for Treatment of Meningitis Caused by Penicillin-Resistant Streptococcus pneumoniae in Rabbits. Antimicrob. Agents Chemother. 46: 1760-1765 [Abstract] [Full Text]  
  • Nau, R., Eiffert, H. (2002). Modulation of Release of Proinflammatory Bacterial Compounds by Antibacterials: Potential Impact on Course of Inflammation and Outcome in Sepsis and Meningitis. Clin. Microbiol. Rev. 15: 95-110 [Abstract] [Full Text]  
  • Rodriguez-Cerrato, V., McCoig, C. C., Michelow, I. C., Ghaffar, F., Jafri, H. S., Hardy, R. D., Patel, C., Olsen, K., McCracken, G. H. Jr. (2001). Pharmacodynamics and Bactericidal Activity of Moxifloxacin in Experimental Escherichia coli Meningitis. Antimicrob. Agents Chemother. 45: 3092-3097 [Abstract] [Full Text]  
  • Rodriguez-Cerrato, V., Ghaffar, F., Saavedra, J., Michelow, I. C., Hardy, R. D., Iglehart, J., Olsen, K., McCracken, G. H. Jr. (2001). BMS-284756 in Experimental Cephalosporin-Resistant Pneumococcal Meningitis. Antimicrob. Agents Chemother. 45: 3098-3103 [Abstract] [Full Text]  
  • Lister, P. D., Sanders, C. C. (2001). Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 47: 811-818 [Abstract] [Full Text]  
  • Destache, C. J., Pakiz, C. B., Larsen, C., Owens, H., Dash, A. K. (2001). Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. J Antimicrob Chemother 47: 611-615 [Abstract] [Full Text]  
  • Cubbon, M. D., Masterton, R. G. (2000). New quinolones--a fresh answer to the pneumococcus. J Antimicrob Chemother 46: 869-872 [Full Text]  
  • Smirnov, A., Wellmer, A., Gerber, J., Maier, K., Henne, S., Nau, R. (2000). Gemifloxacin Is Effective in Experimental Pneumococcal Meningitis. Antimicrob. Agents Chemother. 44: 767-770 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»